title: [Treatment of cutaneous human papilloma virus, poxvirus and herpes simplex virus infections with topical cidofovir in HIV positive patients].
abstract: BACKGROUND
  Cidofovir (Vistide) is an antiviral marketed for the treatment of cytomegalovirus retinitis. Clinical efficacy has been reported with its broad antiviral spectrum that includes poxvirus, human papilloma virus and Herpes simplex. In immunodepressed patients, these infectious dermatoses are often recurrent and resistant. In an open study, we assessed the efficacy and clinical tolerance of cidofovir gel at 1 p. 100.
  
  
  METHODS
  Twelve HIV-infected adults were included. Cidofovir gel at 1 p. 100 was applied directly on the lesions, once a day, for two weeks on the molluscum and condylomas, four weeks on the warts and one week on the chronic herpes.
  
  
  RESULTS
  Four patients presented with warts and 3 of them with verruca plana. In 2 of the verruca plana patients, regression was complete although relapse was observed. Two failures were noted. Local application of the gel was not tolerated by one patient suffering from condylomas of the penis. Four patients presented with molluscum contagiosum. Two complete regressions with strong local reaction and two partial regressions were observed. The latter two patients exhibited severe immunodepression, one of them subsequently received infusions of cidofovir. Two women suffering from vulvar and perianal herpes resistant to acyclovir were treated for one week with cidofovir gel at 1 p. 100: no response was obtained. One of the patients stopped treatment because of local intolerance. A third, less immunodepressed, woman responded partially.
  
  
  CONCLUSIONS
  In HIV-positive patients, cidofovir in topical form appears to be indicated in extensive and confluent molluscum contagiosum. However, the effect occurs at the cost of local inflammation. The results are disappointing in papillomavirus lesions and in chronic acyclovir-resistant herpes ulcerations, efficacy is debatable.
authors.affiliation: Division des Maladies Infectieuses, Hôpital Cantonal Universitaire de Genève, 24 rue Micheli-du-Crest, 1211 Genève 14, Switzerland. laurence.trellu@hcuge.ch
authors.forename: L
authors.initials: L
authors.lastname: Toutous-Trellu
authors.forename: B
authors.initials: B
authors.lastname: Hirschel
authors.forename: V
authors.initials: V
authors.lastname: Piguet
authors.forename: V
authors.initials: V
authors.lastname: Schiffer
authors.forename: J-H
authors.initials: JH
authors.lastname: Saurat
authors.forename: M
authors.initials: M
authors.lastname: Pechère
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D000077404:Cidofovir; D003596:Cytosine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D006561:Herpes Simplex / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage*; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000150:complications / Q000188:drug therapy*; D011213:Poxviridae Infections / Q000150:complications / Q000188:drug therapy*; D017193:Skin Diseases, Viral / Q000150:complications / Q000188:drug therapy*
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir